HRP20201944T1 - Inhibitori kinaze povezane sa tropomiozinom (trk) - Google Patents

Inhibitori kinaze povezane sa tropomiozinom (trk) Download PDF

Info

Publication number
HRP20201944T1
HRP20201944T1 HRP20201944TT HRP20201944T HRP20201944T1 HR P20201944 T1 HRP20201944 T1 HR P20201944T1 HR P20201944T T HRP20201944T T HR P20201944TT HR P20201944 T HRP20201944 T HR P20201944T HR P20201944 T1 HRP20201944 T1 HR P20201944T1
Authority
HR
Croatia
Prior art keywords
alkyl
cycloalkyl
heteroaryl
methoxy
aryl
Prior art date
Application number
HRP20201944TT
Other languages
English (en)
Inventor
John L. Kane
Gloria Matthews
Markus Metz
Michael Kothe
Jinyu Liu
Andrew Scholte
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of HRP20201944T1 publication Critical patent/HRP20201944T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/5022—Aromatic phosphines (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (15)

1. Spoj koji sadrži strukturu formule (II): [image] naznačen time što: n je 1, 2, 3, 4 ili 5; m je 1; Q1 je (C2-C9)heteroaril po želji supstituiran s jednom do četiri skupine odabrane od (C1-C10)alkil, (C2-C9)heteroalkil, (C3-C10)cikloalkil, (C2-C9)heterocikloalkil, (C6-C14)aril, (C2-C9)heteroaril, (C1-C10)alkilamin, (C1-C10)alkil-C(O)O-, COOH-(C1-C10)alkil, COOH-(C3-C10)cikloalkil, (C1-C10)alkil-O-, -OH, -NH2, R7R8N-, R7R8N(O)C-, R7(O)CR8N-, F3C-, NC-, (C3-C10)alkil(O)P-, (C3-C10)alkil-S-, (C3-C10)cikloalkil-S-, (C6-C14)aril-S-, (C2-C9)heteroalkil-S-, (C2-C9)heterocikloalkil-S-, (C2-C9)heteroaril-S-, (C3-C10)alkil(O)S-, (C3-C10)cikloalkil(O)S-, (C6-C14)aril(O)S-, (C2-C9)heteroalkil(O)S-, (C2-C9)heterocikloalkil(O)S-, (C2-C9)heteroaril(O)S-, (C3-C10)alkil-O2S-, (C3-C10)cikloalkil-O2S-, (C6-C14)aril-O2S-, (C2-C9)heteroalkil-O2S-, (C2-C9)heterocikloalkil-O2S-, (C2-C9)heteroaril-O2S-, ili R7R8NO2S-, pri čemu R7 i R8 su svaki neovisno H, (C1-C10)alkil, (C2-C9)heteroalkil, (C3-C10)cikloalkil, (C2-C9)heterocikloalkil, (C6-C14)aril, ili (C2-C9)heteroaril; Q2 je (C6-C14)aril, (C2-C9)heteroaril, (C3-C10)cikloalkil, ili (C2-C9)heterocikloalkil, pri čemu (C6-C14)aril, (C2-C9)heteroaril, (C3-C10)cikloalkil, ili (C2-C9)heterocikloalkil je po želji supstituiran s jednom do četiri skupine odabrane od (C1-C10)alkil, (C2-C9)heteroalkil, (C3-C10)cikloalkil, (C2-C9)heterocikloalkil, (C6-C14)aril, (C2-C9)heteroaril, (C1-C10)alkilamin, (C1-C10)alkil-C(O)O-, COOH-(C1-C10)alkil, COOH-(C3-C10)cikloalkil, (C1-C10)alkil-O-, -OH, -NH2, R7R8N-, R7R8N(O)C-, R7(O)CR8N-, F3C-, NC-, (C3-C10)alkil(O)P-, (C3-C10)alkilS-, (C3-C10)cikloalkil-S-, (C6-C14)aril-S-, (C2-C9)heteroalkil-S-, (C2-C9)heterocikloalkil-S-, (C2-C9)heteroaril-S-, (C3-C10)alkil(O)S-, (C3-C10)cikloalkil(O)S-, (C6-C14)aril(O)S-, (C2-C9)heteroalkil(O)S-, (C2-C9)heterocikloalkil(O)S-, (C2-C9)heteroaril(O)S-, (C3-C10)alkil-O2S-, (C3-C10)cikloalkil-O2S-, (C6-C14)aril-O2S-, (C2-C9)heteroalkil-O2S-, (C2-C9)heterocikloalkil-O2S-, (C2-C9)heteroaril-O2S-, ili R7R8NO2S-, pri čemu R7 i R8 su svaki neovisno H, (C1-C10)alkil, (C2-C9)heteroalkil, (C3-C10)cikloalkil, (C2-C9)heterocikloalkil, (C6-C14)aril, ili (C2-C9)heteroaril; X je CH, N, ili CR9, pri čemu R9 je (C1-C10)alkil, (C2-C9)heteroalkil, (C3-C10)cikloalkil, (C2-C9)heterocikloalkil, (C6-C14)aril, (C2-C9)heteroaril, (C1-C10)alkilamin, (C1-C10)alkil-C(O)O-, COOH-(C1-C10)alkil, COOH-(C3-C10)cikloalkil, (C1-C10)alkil-O-, -OH, ili -NH2 R1 je H, halo, (C1-C10)alkil, (C2-C9)heteroalkil, (C1-C10)alkilamin, ili NH2; i R2 je H, halo, (C1-C10)alkil, (C2-C9)heteroalkil, (C1-C10)alkilamin, (C1-C10)alkil-O-, ili NH2; ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema patentnom zahtjevu 1, naznačen time što n je 1, 2, ili 3.
3. Spoj prema patentnom zahtjevu 1, naznačen time što n je 1.
4. Spoj prema patentnom zahtjevu 1, naznačen time što Q2 je (C6-C14)aril ili (C2-C9)heteroaril, pri čemu je (C6-C14)aril ili (C2-C9)heteroaril po želji supstituiran s jednom do četiri skupine odabrane od (C1-C10)alkil, (C2-C9)heteroalkil, (C3-C10)cikloalkil, (C2-C9)heterocikloalkil, (C6-C14)aril, (C2-C9)heteroaril, (C1-C10)alkilamin, (C1-C10)alkil-C(O)O-, COOH-(C1-C10)alkil, COOH-(C3-C10)cikloalkil, (C1-C10)alkil-O-, -OH, -NH2, R7R8N-, R7R8N(O)C-, R7(O)CR8N-, F3C-, NC-, (C3-C10)alkil(O)P-, (C3-C10)alkil-S-, (C3-C10)cikloalkil-S-, (C6-C14)aril-S-, (C2-C9)heteroalkil-S-, (C2-C9)heterocikloalkil-S-, (C2-C9)heteroaril-S-, (C3-C10)alkil(O)S-, (C3-C10)cikloalkil(O)S-, (C6-C14)aril(O)S-, (C2-C9)heteroalkil(O)S-, (C2-C9)heterocikloalkil(0)S-, (C2-C9)heteroaril(O)S-, (C3-C10)alkil-O2S-, (C3-C10)cikloalkil-O2S-, (C6-C14)aril-O2S-, (C2-C9)heteroalkil-O2S-, (C2-C9)heterocikloalkil-O2S-, (C2-C9)heteroaril-O2S-, ili R7R8NO2S-, pri čemu R7 i R8 su svaki neovisno H, (C1-C10)alkil, (C2-C9)heteroalkil, (C3-C10)cikloalkil, (C2-C9)heterocikloalkil, (C6-C14)aril, ili (C2-C9)heteroaril
5. Spoj prema patentnom zahtjevu 1, naznačen time što X je CH ili N.
6. Spoj prema patentnom zahtjevu 1, naznačen time što R1 je H, halo, NH2, ili (C1-C10)alkil.
7. Spoj prema patentnom zahtjevu 1, naznačen time što R2 je H, halo, (C1-C10)alkil, ili (C1-C10)alkil-O-.
8. Spoj prema patentnom zahtjevu 1, naznačen time što se bira iz skupine koja sadrži: 1-(3-Metoksi-4-((4-metoksibenzil)oksi)benzil)-5-(1-metil-1H-pirazol-4-il)-1H-benzo[d]imidazol-2-amin, 1-(3-Metoksi-4-((4-metoksibenzil)oksi)benzil)-5-(pirimidin-5-il)-1H-benzo[d]imidazol-2-amin, 1-(3-Metoksi-4-((4-metoksibenzil)oksi)benzil)-5-(piridin-4-il)-1H-benzo[d]imidazol-2-amin, 3-(3-metoksi-4-((6-metoksipiridin-3-il)metoksi)benzil)-6-(1-(piperidin-4-il)-1H-pirazol-4-il)-3H-imidazo[4,5-b]piridin, 1-(3-Metoksi-4-((6-metoksipiridin-3-il)metoksi)benzil)-5-(4-(piperidin-3-il)-1H-1,2,3-triazol-1-il)-1H-benzo[d]imidazol, 3-(3-Metoksi-4-((4-metoksibenzil)oksi)benzil)-6-(1-metil-1H-pirazol-4-il)-3H-imidazo[4,5-b]piridin-2-amin, 3-(3-Metoksi-4-((6-metoksipiridin-3-il)metoksi)benzil)-6-(1-(piperidin-4-il)-1H-pirazol-4-il)-3H-imidazo[4,5-b]piridin, 3-(3-Metoksi-4-((6-metilpiridin-3-il)metoksi)benzil)-6-(1-(piperidin-4-il)-1H-pirazol-4-il)-3H-imidazo[4,5-b]piridin, 3-(3-(3-Metoksi-4-((6-metoksipiridin-3-il)metoksi)benzil)-3H-imidazo[4,5-b]piridin-6-il)-5-(piperidin-4-il)-1,2,4-oksadiazol, 2-(3-(3-Metoksi-4-((6-metoksipiridin-3-il)metoksi)benzil)-3H-imidazo[4,5-b]piridin-6-il)-5-(piperidin-4-il)-1,3,4-oksadiazol, 2-(1-(3-(3-Metoksi-4-((6-metoksipiridin-3-il)metoksi)benzil)-3H-imidazo[4,5-blpiridin-6-il)-1H-1,2,3-triazol-4-il)propan-2-amin, i 3-(3-Metoksi-4-((6-metoksipiridin-3-il)metoksi)benzil)-6-(4-(piperidin-3-il)-1H-1,2,3-triazol-1-il)-3H-imidazo[4,5-b]piridin, ili njegova farmaceutski prihvatljiva sol.
9. Spoj prema patentnom zahtjevu 1, naznačen time što je spoj: [image] ili njegova farmaceutski prihvatljiva sol.
10. Farmaceutski pripravak naznačen time što sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 9, ili njegovu farmaceutski prihvatljivu sol.
11. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak prema zahtjevu 10 naznačen time što se koristi u postupku liječenja upalnih bolesti, autoimunih bolesti, oštećenja metabolizma kostiju ili raka kod pacijenta kojem je to potrebno.
12. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak prema zahtjevu 10 naznačen time što se koristi u postupku liječenja osteoartritisa kod pacijenta kojem je to potrebno.
13. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak prema zahtjevu 10 naznačen time što se koristi u postupku liječenja boli kod pacijenta kojem je to potrebno.
14. Spoj za uporabu prema patentnom zahtjevu 13, naznačen time što je bol postoperativna bol.
15. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak prema zahtjevu 10 naznačen time što se koristi u postupku liječenja boli povezane s osteoartritisom kod pacijenta kojem je to potrebno.
HRP20201944TT 2013-12-10 2020-12-04 Inhibitori kinaze povezane sa tropomiozinom (trk) HRP20201944T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361914128P 2013-12-10 2013-12-10
US201462040750P 2014-08-22 2014-08-22
EP14824251.4A EP3080108B1 (en) 2013-12-10 2014-12-10 Tropomyosin-related kinase (trk) inhibitors
PCT/US2014/069469 WO2015089139A1 (en) 2013-12-10 2014-12-10 Tropomyosin-related kinase (trk) inhibitors

Publications (1)

Publication Number Publication Date
HRP20201944T1 true HRP20201944T1 (hr) 2021-02-05

Family

ID=52282924

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201944TT HRP20201944T1 (hr) 2013-12-10 2020-12-04 Inhibitori kinaze povezane sa tropomiozinom (trk)

Country Status (35)

Country Link
US (7) US9067914B1 (hr)
EP (2) EP3080108B1 (hr)
JP (3) JP6588437B2 (hr)
KR (1) KR102368956B1 (hr)
CN (2) CN106232597B (hr)
AU (1) AU2014363894C1 (hr)
BR (1) BR112016013185A2 (hr)
CA (1) CA2933246A1 (hr)
CL (1) CL2016001409A1 (hr)
CR (1) CR20160285A (hr)
DK (1) DK3080108T3 (hr)
DO (1) DOP2016000127A (hr)
EA (1) EA034429B1 (hr)
EC (1) ECSP16059072A (hr)
ES (1) ES2838004T3 (hr)
HK (1) HK1232225A1 (hr)
HR (1) HRP20201944T1 (hr)
HU (1) HUE052291T2 (hr)
IL (1) IL246054B (hr)
LT (1) LT3080108T (hr)
MX (1) MX2016007487A (hr)
MY (1) MY183629A (hr)
PE (1) PE20160992A1 (hr)
PH (1) PH12016501073B1 (hr)
PL (1) PL3080108T3 (hr)
PT (1) PT3080108T (hr)
RS (1) RS61296B1 (hr)
SG (2) SG10201804842WA (hr)
SI (1) SI3080108T1 (hr)
TN (1) TN2016000234A1 (hr)
TW (2) TWI731317B (hr)
UA (1) UA121651C2 (hr)
UY (1) UY35875A (hr)
WO (1) WO2015089139A1 (hr)
ZA (1) ZA201603833B (hr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI731317B (zh) 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
SG11201704872RA (en) * 2014-12-18 2017-07-28 Genzyme Corp Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors
KR102665765B1 (ko) * 2015-07-20 2024-05-10 젠자임 코포레이션 콜로니 자극 인자-1 수용체(csf-1r) 저해제
ES2919280T3 (es) 2017-05-04 2022-07-22 Bayer Cropscience Ag Derivados de 2-{[2-(feniloximetil)piridin-5-il]oxi}-etanamina y compuestos relacionados como pesticidas, por ejemplo para la protección de plantas
CN110156813B (zh) * 2018-02-13 2023-07-25 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
CN108822103A (zh) * 2018-07-28 2018-11-16 刘凤娟 一种咪唑并[4,5-b]吡啶化合物及其制备方法和应用
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CN113727984B (zh) 2019-05-21 2024-03-15 浙江海正药业股份有限公司 大环类衍生物、及其制备方法和用途
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
EP4180428A1 (en) * 2021-11-12 2023-05-17 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59181263A (ja) * 1983-03-29 1984-10-15 Nippon Nohyaku Co Ltd ベンズイミダゾ−ル誘導体
JPS60158180A (ja) * 1984-01-30 1985-08-19 Sumitomo Chem Co Ltd ベンズイミダゾ−ル誘導体、その製造法およびそれを有効成分とする殺虫、殺ダニ剤
US4612323A (en) * 1983-06-27 1986-09-16 Sumitomo Chemical Company, Limited Insecticidal and acaricidal derivatives of 1-benzylbenzimidazole
JPS6117569A (ja) * 1984-07-03 1986-01-25 Sumitomo Chem Co Ltd ベンズイミダゾ−ル誘導体およびそれを有効成分とする殺ダニ剤
JPS61151176A (ja) * 1984-12-24 1986-07-09 Sumitomo Chem Co Ltd ベンズイミダゾール誘導体およびそれを有効成分とする殺虫、殺ダニ剤
EP0515535A4 (en) * 1990-02-13 1996-01-17 Merck & Co Inc Angiotensin ii antagonists incorporating a substituted benzyl element
DE4219534A1 (de) 1992-02-19 1993-12-16 Thomae Gmbh Dr K Substituierte Biphenylylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DK154092D0 (da) * 1992-12-23 1992-12-23 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
US5702637A (en) 1995-04-19 1997-12-30 Minnesota Mining And Manufacturing Company Liquid crystal compounds having a chiral fluorinated terminal portion
DE19718181A1 (de) * 1997-04-30 1998-11-05 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
US6348474B1 (en) * 1997-06-27 2002-02-19 Fujisawa Pharmaceutical Co., Ltd. Sulfonamide compounds and medicinal use thereof
CN1268137A (zh) * 1997-07-03 2000-09-27 杜邦药品公司 治疗神经失调的咪唑并嘧啶和咪唑并吡啶
GB9825652D0 (en) * 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
HUP0104549A3 (en) * 1998-12-04 2002-12-28 Fujisawa Pharmaceutical Co Imidazo-pyridine sulfonamide derivatives and pharmaceutical compositions thereof
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
US7491748B2 (en) * 2001-08-09 2009-02-17 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
GB0122190D0 (en) 2001-09-14 2001-10-31 Qinetiq Ltd Novel compounds
US20040002145A1 (en) 2002-03-18 2004-01-01 Shewchuk Lisa Marie Crystal structure of liganded cFMS kinase domain
WO2003099276A1 (en) 2002-05-10 2003-12-04 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
TWI332003B (en) 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
EP1731524A4 (en) 2004-03-31 2009-05-20 Kissei Pharmaceutical PHENOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE, AND ITS MEDICINAL USE
ES2346665T3 (es) * 2004-05-07 2010-10-19 Warner-Lambert Company Llc Derivados de fenol y tiofenol 3- o 4-monosustituidos utiles como ligandos de h3.
AU2005307818A1 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocyclylbiphenyl derivates as protein Tyrosine phosphatase inhibitors
WO2006087530A1 (en) * 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
JP2006273879A (ja) 2005-03-25 2006-10-12 Fuji Photo Film Co Ltd カラー表示素子及びカラー表示方法
WO2007037534A1 (ja) 2005-09-30 2007-04-05 Banyu Pharmaceutical Co., Ltd. ２－へテロアリール置換インドール誘導体
CN1947717B (zh) 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
US7851484B2 (en) 2007-03-30 2010-12-14 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2008129255A1 (en) 2007-04-18 2008-10-30 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
ES2593279T3 (es) 2007-08-29 2016-12-07 Methylgene Inc. Procesos e intermedios para preparar inhibidores de cinasa heterocíclicos condensados
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
RU2553681C2 (ru) 2009-10-29 2015-06-20 Вектура Лимитед N-содержащие гетероарильные производные в качестве ингибиторов jak3 киназы
RU2012120784A (ru) * 2009-11-12 2013-12-20 Селвита С.А. Соединение, способ его получения, фармацевтическая композиция, применение соединения, способ модулирования или регулирования сериновых/треониновых киназ и средство, модулирующее сериновые/треониновые киназы
US8604217B2 (en) * 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
JP5504969B2 (ja) 2010-02-25 2014-05-28 株式会社島津製作所 質量分析装置
US20130165426A1 (en) 2010-07-06 2013-06-27 Université de Montréal Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
KR20130133905A (ko) 2011-04-05 2013-12-09 화이자 리미티드 트로포미오신-관련 키나제의 억제제인 피롤로[2,3-d]피리미딘 유도체
WO2013088257A1 (en) * 2011-12-12 2013-06-20 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors
WO2013176970A1 (en) 2012-05-22 2013-11-28 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
JP6117569B2 (ja) 2013-02-28 2017-04-19 三甲株式会社 ボックスパレット
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
TWI731317B (zh) * 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
SG11201704872RA (en) 2014-12-18 2017-07-28 Genzyme Corp Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors

Also Published As

Publication number Publication date
US20150158847A1 (en) 2015-06-11
CN106232597B (zh) 2019-12-17
RS61296B1 (sr) 2021-02-26
US9067914B1 (en) 2015-06-30
EP3848368A1 (en) 2021-07-14
JP2019163330A (ja) 2019-09-26
IL246054B (en) 2020-09-30
JP2016539957A (ja) 2016-12-22
US9611265B2 (en) 2017-04-04
JP7008782B2 (ja) 2022-02-10
LT3080108T (lt) 2021-01-11
MX2016007487A (es) 2016-10-13
TN2016000234A1 (en) 2017-10-06
WO2015089139A1 (en) 2015-06-18
UA121651C2 (uk) 2020-07-10
JP6588437B2 (ja) 2019-10-09
US20190183903A1 (en) 2019-06-20
DOP2016000127A (es) 2016-08-15
AU2014363894A1 (en) 2016-06-30
ECSP16059072A (es) 2017-05-31
HK1232225A1 (zh) 2018-01-05
TWI663159B (zh) 2019-06-21
SG11201604621UA (en) 2016-07-28
MY183629A (en) 2021-03-03
BR112016013185A2 (pt) 2017-08-08
US9174986B2 (en) 2015-11-03
CN106232597A (zh) 2016-12-14
US11406644B2 (en) 2022-08-09
PH12016501073A1 (en) 2016-07-11
KR20160095074A (ko) 2016-08-10
PT3080108T (pt) 2020-12-23
CA2933246A1 (en) 2015-06-18
DK3080108T3 (en) 2020-12-14
US20170224704A1 (en) 2017-08-10
US11878024B2 (en) 2024-01-23
EA201691196A1 (ru) 2016-10-31
US20150274725A1 (en) 2015-10-01
US20210169894A1 (en) 2021-06-10
JP2021054843A (ja) 2021-04-08
NZ721051A (en) 2021-10-29
US10166239B2 (en) 2019-01-01
IL246054A0 (en) 2016-08-02
TW201609689A (zh) 2016-03-16
SI3080108T1 (sl) 2021-01-29
EP3080108B1 (en) 2020-10-07
PE20160992A1 (es) 2016-10-19
PL3080108T3 (pl) 2021-05-04
EA034429B1 (ru) 2020-02-06
PH12016501073B1 (en) 2016-07-11
US20230080874A1 (en) 2023-03-16
AU2014363894C1 (en) 2019-08-29
ES2838004T3 (es) 2021-07-01
AU2014363894B2 (en) 2019-05-30
HUE052291T2 (hu) 2021-04-28
TW202003485A (zh) 2020-01-16
KR102368956B1 (ko) 2022-02-28
SG10201804842WA (en) 2018-07-30
EP3080108A1 (en) 2016-10-19
CL2016001409A1 (es) 2017-01-20
UY35875A (es) 2015-07-31
CR20160285A (es) 2016-09-09
CN111171021A (zh) 2020-05-19
ZA201603833B (en) 2019-01-30
TWI731317B (zh) 2021-06-21
US20150191466A1 (en) 2015-07-09

Similar Documents

Publication Publication Date Title
HRP20201944T1 (hr) Inhibitori kinaze povezane sa tropomiozinom (trk)
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
HRP20180382T1 (hr) Inhibitori protein kinaze
HRP20210447T1 (hr) Piridinski spoj
HRP20140953T1 (hr) Morfolino pirimidini i njihova uporaba za lijeäśenje
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
PH12014502040A1 (en) Heterocyclyl compounds
HRP20230595T1 (hr) Inhibitori lizina specifične demetilaze-1
TN2018000219A1 (en) Soluble guanylate cyclase stimulators
RU2012136643A (ru) [5,6]- гетероциклическое соединение
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
RU2015148189A (ru) ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1
NZ708864A (en) Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
RU2011100786A (ru) Производные имидазопиридина в качестве ингибиторов рецепторных тирозинкиназ
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
JP2016506962A5 (hr)
WO2017087808A8 (en) Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
IN2014DN08939A (hr)
RU2017118165A (ru) Ингибиторы энхансера гомолога 2 zestes
EA201590021A1 (ru) Новые замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса
RU2015101102A (ru) Гетероароматическое метильное производное циклического амина
EA201590022A1 (ru) Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса
JP2014510147A5 (hr)
EA201490630A1 (ru) 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы